July 04, 2026 05:48 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Why can't citizens protest against the government? They are being made slaves by slapping cases': Bombay HC slams Mumbai Police, quashes activist's externment | 'First he cheats on me...': Siya Goyal's old pub video goes viral amid probe into fiancé Ketan Agarwal's alleged murder | Ronaldo's goal, Ramos' last-gasp winner send Portugal past Croatia, set up Spain clash | India-US trade deal almost done! Piyush Goyal hints at breakthrough | Ram Mandir donation scam: Champat Rai points finger at his own driver | PM Modi welcomes Japanese PM Sanae Takaichi as India-Japan ties enter a new era | 'Not an isolated incident': India slams Pakistan after 125-year-old historic Gurdwara is demolished | Ram Mandir donation theft: Six accused were employed by Varanasi-based security firm, probe reveals | Ayodhya Ram Temple donation theft: Probe says majority of money was allegedly stolen during Kumbh Mela | Commercial LPG price slashed by Rs 183.50 from July 1; check new rates in Delhi, Mumbai, Kolkata and Chennai
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm